Cite
HARVARD Citation
Chuang, L. et al. (2017). Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective. Journal of medical economics. pp. 1127-1134. [Online].